---
layout: default
title: Lynestrenol
parent: 僅模型預測 (L5)
nav_order: 84
evidence_level: L5
indication_count: 5
---

# Lynestrenol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lynestrenol: Drug Repurposing Evaluation — Insufficient Data for Full Assessment

## One-Sentence Summary

Lynestrenol (DrugBank ID: DB12474) is a synthetic progestogen with no approved indications currently on record in Taiwan. The TxGNN repurposing pipeline returned **no predicted indications** for this candidate, and critical data including mechanism of action and safety warnings are not yet available — a complete repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indication on record in Taiwan |
| Predicted New Indication | No TxGNN prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction unavailable; no supporting studies |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Is Available

The TxGNN model did not return any repurposing candidates for Lynestrenol in this run. Two likely explanations exist:

1. **Knowledge Graph coverage gap**: Lynestrenol may have limited node connectivity in the TxGNN knowledge graph if its pharmacological relationships (targets, pathways, disease associations) are under-annotated.
2. **Missing MOA input**: Mechanism of action data was flagged as a high-severity data gap (`DG002`). Without MOA information, the model lacks the mechanistic signal needed to generate confident disease-association predictions.

Additionally, Lynestrenol has zero regulatory records in Taiwan, which eliminates the possibility of drawing on local approval history to anchor predictions.

> Currently, detailed mechanism of action data is not available. Based on known pharmacological class, Lynestrenol is a synthetic progestogen. Its therapeutic applicability in any new indication cannot be mechanistically evaluated until MOA data is retrieved from DrugBank.

---

## Taiwan Market Information

No authorization records found in the Taiwan TFDA database.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN repurposing predictions, no approved indications, and no mechanism of action or safety data for Lynestrenol. Proceeding with evaluation at this stage would rely entirely on speculation without supporting evidence.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Retrieve TFDA package insert (PDF) to extract warnings, contraindications, and dosing safety data
- **[High — DG002]** Query DrugBank API for full MOA, targets, and pharmacological categories
- **Re-run TxGNN pipeline** after MOA data is populated — confirm that Lynestrenol nodes are properly linked in the knowledge graph
- **Check international regulatory status** — confirm approved indications in EMA, FDA, or other jurisdictions to provide an anchor indication for the repurposing title and mechanistic analysis
- **Validate KG node coverage** for Lynestrenol: if the node is isolated or sparsely connected, manual literature-based edge annotation may be required before a prediction can be generated
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

